FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210423162> ?p ?o ?g. }

• W4210423162 abstract "To investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy.Literature searching was performed in PubMed, Embase, and The Cochrane Library up to 2021. Prediction models were firstly established using data from phase III randomized controlled trials (RCTs) and then externally validated in phase II and retrospective studies. Correlation analysis was evaluated by a weighted linear regression model at both trial and arm levels. Cross-validation was performed to assess the consistency and robustness of the established models.37 studies, including 15 phase III RCTs, 12 phase II studies, and 10 retrospective studies, were selected in the final analysis. In trial-level surrogacy, a very good correlation was observed between hazard ratios (HRs) of PFS/TTP and OS (R2 = 0.783, 95% CI 0.771-0.794). In arm-level surrogacy, very good correlations were also observed between 2-year (R2 = 0.823, 95% CI 0.814-0.832), 3-year (R2 = 0.843, 95% CI 0.833-0.850), 5-year (R2 = 0.852, 95% CI 0.843-0.859) PFS/TTP, and 5-year OS. An excellent correlation was observed between 4-year PFS/TTP and 5-year OS (R2 = 0.906, 95% CI 0.901-0.910). Cross-validation demonstrated reasonable overall consistency. External validation in phase II and retrospective studies showed good agreement (R2, 0.728-0.824).PFS/TTP was a valid surrogate endpoint for OS in patients with LS-SCLC receiving combined chemoradiotherapy. The finding provides high-level evidence to support PFS/TTP as the primary endpoint in clinical trials so as to speed up introducing novel agents to the treatment of LS-SCLC." @default.
• W4210423162 created "2022-02-08" @default.
• W4210423162 creator A5013850008 @default.
• W4210423162 creator A5027610105 @default.
• W4210423162 creator A5031138415 @default.
• W4210423162 creator A5034022345 @default.
• W4210423162 creator A5034291484 @default.
• W4210423162 creator A5035701638 @default.
• W4210423162 creator A5067714130 @default.
• W4210423162 creator A5079594267 @default.
• W4210423162 creator A5089768060 @default.
• W4210423162 date "2022-01-28" @default.
• W4210423162 modified "2023-10-17" @default.
• W4210423162 title "Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis" @default.
• W4210423162 cites W1521811891 @default.
• W4210423162 cites W1552379896 @default.
• W4210423162 cites W1594082902 @default.
• W4210423162 cites W1863488026 @default.
• W4210423162 cites W1885320430 @default.
• W4210423162 cites W1898381946 @default.
• W4210423162 cites W1976228473 @default.
• W4210423162 cites W1989919753 @default.
• W4210423162 cites W1991585418 @default.
• W4210423162 cites W2010674816 @default.
• W4210423162 cites W2011868684 @default.
• W4210423162 cites W2020393160 @default.
• W4210423162 cites W2020882823 @default.
• W4210423162 cites W2021987821 @default.
• W4210423162 cites W2047994314 @default.
• W4210423162 cites W2078295303 @default.
• W4210423162 cites W2081953717 @default.
• W4210423162 cites W2088095316 @default.
• W4210423162 cites W2093259073 @default.
• W4210423162 cites W2108348820 @default.
• W4210423162 cites W2112109633 @default.
• W4210423162 cites W2117976634 @default.
• W4210423162 cites W2127061702 @default.
• W4210423162 cites W2129991620 @default.
• W4210423162 cites W2131219536 @default.
• W4210423162 cites W2139329867 @default.
• W4210423162 cites W2140075859 @default.
• W4210423162 cites W2141299823 @default.
• W4210423162 cites W2144539352 @default.
• W4210423162 cites W2145404936 @default.
• W4210423162 cites W2160012348 @default.
• W4210423162 cites W2161693686 @default.
• W4210423162 cites W2163056448 @default.
• W4210423162 cites W2170639393 @default.
• W4210423162 cites W2174863158 @default.
• W4210423162 cites W2228221433 @default.
• W4210423162 cites W2323020638 @default.
• W4210423162 cites W2334828881 @default.
• W4210423162 cites W2528200937 @default.
• W4210423162 cites W2592484902 @default.
• W4210423162 cites W2699278758 @default.
• W4210423162 cites W2753065806 @default.
• W4210423162 cites W2765782352 @default.
• W4210423162 cites W2893960509 @default.
• W4210423162 cites W2986084302 @default.
• W4210423162 cites W2997099970 @default.
• W4210423162 cites W3014332654 @default.
• W4210423162 cites W3035570024 @default.
• W4210423162 cites W3041289786 @default.
• W4210423162 cites W3048896255 @default.
• W4210423162 cites W3108819942 @default.
• W4210423162 cites W3135059838 @default.
• W4210423162 cites W3138600007 @default.
• W4210423162 cites W3140025388 @default.
• W4210423162 cites W3161102817 @default.
• W4210423162 cites W3166170782 @default.
• W4210423162 cites W3199068224 @default.
• W4210423162 cites W3210386864 @default.
• W4210423162 cites W3214539747 @default.
• W4210423162 cites W4238763148 @default.
• W4210423162 cites W851077011 @default.
• W4210423162 doi "https://doi.org/10.3389/fonc.2022.810580" @default.
• W4210423162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35155246" @default.
• W4210423162 hasPublicationYear "2022" @default.
• W4210423162 type Work @default.
• W4210423162 citedByCount "0" @default.
• W4210423162 crossrefType "journal-article" @default.
• W4210423162 hasAuthorship W4210423162A5013850008 @default.
• W4210423162 hasAuthorship W4210423162A5027610105 @default.
• W4210423162 hasAuthorship W4210423162A5031138415 @default.
• W4210423162 hasAuthorship W4210423162A5034022345 @default.
• W4210423162 hasAuthorship W4210423162A5034291484 @default.
• W4210423162 hasAuthorship W4210423162A5035701638 @default.
• W4210423162 hasAuthorship W4210423162A5067714130 @default.
• W4210423162 hasAuthorship W4210423162A5079594267 @default.
• W4210423162 hasAuthorship W4210423162A5089768060 @default.
• W4210423162 hasBestOaLocation W42104231621 @default.
• W4210423162 hasConcept C121608353 @default.
• W4210423162 hasConcept C126322002 @default.
• W4210423162 hasConcept C141341695 @default.
• W4210423162 hasConcept C143998085 @default.
• W4210423162 hasConcept C146357865 @default.
• W4210423162 hasConcept C151730666 @default.
• W4210423162 hasConcept C167135981 @default.
• W4210423162 hasConcept C168563851 @default.
• W4210423162 hasConcept C203092338 @default.

• next